Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Lancet
Faiez ZannadEXAMINE Investigators

Abstract

The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and recent acute coronary syndromes. Concerns about excessive rates of in-hospital heart failure in another DPP-4 inhibitor trial have been reported. We therefore assessed hospital admission for heart failure in the EXAMINE trial. Patients with type 2 diabetes and an acute coronary syndrome event in the previous 15-90 days were randomly assigned alogliptin or placebo plus standard treatment for diabetes and cardiovascular disease prevention. The prespecified exploratory extended MACE endpoint was all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, urgent revascularisation due to unstable angina, and hospital admission for heart failure. The post-hoc analyses were of cardiovascular death and hospital admission for heart failure, assessed by history of heart failure and brain natriuretic peptide (BNP) concentration at baseline. We also assessed changes in N-terminal pro-BNP (NT-pro-BNP) from baseline to 6 months. This study is registered with ClinicalTrials.gov, number NCT00968708. 5380 patients were assigned to alogliptin (n=2701) or placebo (n=2679...Continue Reading

References

Jul 1, 1974·The American Journal of Cardiology·W B KannelW P Castelli
Jan 5, 2000·American Heart Journal·H M KrumholzR I Horwitz
Sep 1, 2007·BMJ : British Medical Journal·Dean T EurichJeffrey A Johnson
Mar 4, 2009·Journal of Cardiac Failure·Alexander A LeungFinlay A McAlister
Jul 25, 2009·Journal of the American College of Cardiology·David AguilarAnita Deswal
Jan 19, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Mads HalbirkHenrik Wiggers
Oct 19, 2010·Circulation. Heart Failure·David AguilarAnita Deswal
Sep 24, 2011·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G de SimoneB V Howard
Sep 15, 2012·European Journal of Heart Failure·Anselm K GittDiethelm Tschöpe
Jan 26, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Richard M CubbonMark T Kearney
Mar 19, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Ayako TakahashiMasafumi Kitakaze
Jun 7, 2013·Circulation·UNKNOWN WRITING COMMITTEE MEMBERSUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Jul 31, 2013·Circulation. Heart Failure·Leonardo dos SantosAdriana C C Girardi
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
May 6, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci

❮ Previous
Next ❯

Citations

Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·R KumarT Walther
Nov 21, 2015·Expert Opinion on Investigational Drugs·Brian TomlinsonZhong-Min Liu
Nov 27, 2015·Expert Opinion on Drug Safety·Daisuke Yabe, Yutaka Seino
Sep 29, 2015·Trends in Cardiovascular Medicine·Sanam Lathief, Silvio E Inzucchi
Jan 16, 2016·Annual Review of Medicine·William B White, William L Baker
Nov 10, 2015·Clinical Therapeutics·Damon A Bell, Gerald F Watts
Dec 20, 2015·Journal of Hypertension·Peter M Nilsson, Javier Diez
Dec 24, 2015·Diabetes Care·UNKNOWN American Diabetes Association
Nov 7, 2015·Journal of Diabetes Investigation·Young Min Cho
Sep 26, 2015·Drugs·Sohita Dhillon
Mar 26, 2016·Journal of the American College of Cardiology·Greer WaldropSanjay Rajagopalan
Mar 1, 2016·Expert Opinion on Drug Safety·Simona CerneaItamar Raz
Oct 16, 2015·Lancet·William B WhiteFaiez Zannad
Oct 16, 2015·Lancet·Martin HülsmannStephanie Neuhold
Jan 26, 2016·Expert Opinion on Pharmacotherapy·Sheila A Doggrell, Simon B Dimmitt
Apr 4, 2016·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Enzo Bonora, Massimo Cigolini
Apr 4, 2016·Cardiovascular Diabetology·Cristiana VitaleKrishna Prasad
Sep 30, 2015·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Sep 2, 2015·Drugs·Esther S Kim, Emma D Deeks
Apr 15, 2016·Science Translational Medicine·Hui WangHongting Zheng
Jul 15, 2015·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·B A KappelM Federici
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jul 19, 2015·Semergen·C Escobar, J A Divisón
May 27, 2015·Lancet·Richard E Gilbert, Henry Krum
Apr 24, 2016·Reviews in Endocrine & Metabolic Disorders·Avivit CahnItamar Raz
Jul 16, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Faiez ZannadGonzalo Calvo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.